Exiqon Expands in US; Sales Headquarters Established

September 12, 2006. Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced it is expanding its US presence by opening a sales, distribution and technical support facility in the heart of the Boston, MA biotech community.

The new entity, Exiqon, Inc., is already operational and is being managed by Michael Kallelis, who serves as President. The offices are located just north of Boston in Woburn, MA.

“As our miRCURY™ LNA brand of microRNA research products continue to rapidly grow, we want to bring distribution, technical support and sales specialists closer to our US customers. We will be able to provide excellent customer support and faster order fulfillment as our sales continue to expand”, said Michael Kallelis, President of Exiqon, Inc. “We also offer a microRNA profiling service for researchers that do not want to carry out these experiments themselves”, he added.

Kallelis continued, “As more customers discover the advantages of our miRCURY™ LNA microarrays, an experienced sales force in the US will further enhance our market awareness and is an essential element for customer satisfaction and continued growth.”

Establishing a US presence will also liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia, where a distributor network is being put in place.

The significance of microRNA in gene expression continues to be published in a growing number of scientific journals. Exiqon’s proprietary LNA™ technology, which forms the basis of the miRCURY™ LNA product line, is especially suited for microRNA research products and several miRCURY™ LNA products are the de facto standard for microRNA researchers.

In July, the company announced it had secured the right to use over 200 human and viral microRNA sequences in diagnostic applications, through two separate co-exclusive license agreements with The Rockefeller University and Garching Innovation, the technology transfer agency of the Max Planck Society. The licenses allow Exiqon to expand into the development of diagnostic products.

About microRNA
microRNAs are a novel class of regulatory RNA molecules with surprisingly wide spread effects on gene regulation. Although recently identified as a new class of molecules, initial studies indicate that microRNAs may regulate as much as one third of all genes in the genome. Thus, microRNAs comprise an up-until-now hidden level of gene regulation.

About Exiqon
Exiqon is a leading provider of high-value gene expression analysis products for the life sciences, research and drug discovery industries. Exiqon’s rapidly growing product offerings integrate innovative chemistries with web-based software tools to help scientists achieve rapid and reliable results. Exiqon markets its products directly on www.exiqon.com or through distributors in the EU and Asia, as well as through its new, dedicated US sales force. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark and in Boston, USA. Please visit our web-site at www.exiqon.com.
xx

Publisher Contact Information:

Exiqon A/S
+45 45 66 08 88
echwald@exiqon.com

Company profile of Exiqon A/S
Past press releases of Exiqon A/S.